Kezar Life Sciences

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating their innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class immunoproteasome inhibitor, is currently in three Phase 2 trials across five separate autoimmune diseases of high unmet need – lupus nephritis, dermatomyositis/polymyositis, and autoimmune hemolytic anemia/immune thrombocytopenia. Additionally, the Company plans to nominate an initial clinical candidate for the treatment of cancer from our protein secretion program before the end of the year.

News Feed